Processing...
Clinical Trials for Liver Cancer
Search
Search
There are 120 active trials for advanced/metastatic liver cancer.
Click on a trial to see more information.
120 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults (≥18) with locally advanced or metastatic solid tumors that are refractory/intolerant to standard therapies or lack standard options (ECOG 0–2; no active CNS/leptomeningeal metastases) receive IV JMT108 every 2 weeks (with possible alternate schedules in expansion). JMT108 is a fully human anti–PD-1 antibody fused to IL-15 intended to combine checkpoint blockade with IL-15–driven activation/proliferation of CD8+ T cells and NK cells, with tumor-specific expansion cohorts including lung, colorectal, hepatocellular, gastric cancers, melanoma, and other solid tumors.
ClinicalTrials.gov ID: NCT07317505
TrialFetch AI summary: Enrolls adults with metastatic or locally advanced unresectable solid tumors (ECOG ≤2; measurable/evaluable by RECIST) with biologic rationale for RBM39 degradation; adolescents ≥16 may enroll for Ewing sarcoma or other supported malignancies, and stable treated brain metastases are allowed. Patients receive oral ST-01156, a small-molecule molecular glue RBM39 degrader (RNA-binding/splicing factor), dosed once daily on a 5-days-on/2-days-off schedule in 28-day cycles with dose escalation to define MTD/RP2D and assess early antitumor activity.
ClinicalTrials.gov ID: NCT07197554
TrialFetch AI summary: Adults with RECIST-measurable advanced solid tumors (excluding primary CNS malignancies), ECOG 0–1, adequate organ function, and controlled/treated CNS disease (if present) after standard therapies are eligible. Patients receive PLT012 IV every 3 weeks, a first-in-class humanized anti-CD36 IgG4 “metabolic checkpoint” monoclonal antibody intended to block CD36-mediated lipid uptake and restore antitumor T-cell function, with treatment continuing until progression or unacceptable toxicity.
ClinicalTrials.gov ID: NCT07337525
TrialFetch AI summary: For patients <30 years with unresectable, relapsed/refractory solid tumors requiring accessible biopsy (Part 2 enriched for fibrolamellar carcinoma; also HCC, DSRCT, and non-CNS malignant rhabdoid tumor), this single-arm study evaluates a 21-day regimen of metronomic oral cyclophosphamide plus PK-guided oral sorafenib (multikinase inhibitor of RAF/VEGFR/PDGFR) with IV bevacizumab (anti–VEGF-A) and IV atezolizumab (anti–PD-L1 checkpoint inhibitor) every 21 days. The trial focuses on safety/RP2D and preliminary response with sorafenib exposure targeting to reduce variability/toxicity.
ClinicalTrials.gov ID: NCT05468359
TrialFetch AI summary: Adults with ECOG 0–1 and measurable advanced selected solid tumors, including SCLC, extrapulmonary high-grade neuroendocrine/small-cell carcinomas, NSCLC, prostate, ovarian, renal, HNSCC, hepatic, gastric, and triple-negative breast cancers, after progression/relapse/intolerance to at least one standard systemic therapy. All patients receive dose-escalated oral EXS74539/REC-4539 monotherapy, a selective reversible LSD1/KDM1A epigenetic inhibitor, to define safety and MTD with preliminary efficacy assessment.
ClinicalTrials.gov ID: NCT07517198
TrialFetch AI summary: Adults with ECOG 0–1 and refractory/relapsed locally advanced unresectable or metastatic solid tumors, including post–PD-1/PD-L1 treated RCC, HCC, gastroesophageal cancer, and endometrial cancer, receive CTX-10726 monotherapy IV every 2 weeks. CTX-10726 is an investigational tetravalent bispecific antibody targeting PD-1 and VEGF-A to combine checkpoint blockade with anti-angiogenic activity.
ClinicalTrials.gov ID: NCT07419841
TrialFetch AI summary: Adults with previously treated unresectable HCC (BCLC C or B not suitable for locoregional therapy), Child-Pugh A, ECOG 0-1, and measurable disease undergo RYZ811 gallium-68 PET to identify GPC3-positive tumors. Eligible patients receive RYZ801, an actinium-225 GPC3-targeted alpha-emitting radiopharmaceutical, with dose escalation/expansion and randomized comparison against standard-of-care systemic therapy.
ClinicalTrials.gov ID: NCT06726161
TrialFetch AI summary: For patients ≥12 years with unresectable/metastatic fibrolamellar hepatocellular carcinoma or adults with other solid tumors harboring the DNAJB1‑PRKACA fusion, including checkpoint‑naïve and some checkpoint‑experienced FLC cohorts. Treatment combines an off‑the‑shelf DNAJB1‑PRKACA junction neoepitope peptide vaccine (adjuvanted with TLR1/2 agonist XS15) with nivolumab (PD‑1 inhibitor) and ipilimumab (CTLA‑4 inhibitor) to augment vaccine‑primed T‑cell responses; a re‑enrollment option may use nivolumab plus vaccine if prior CTLA‑4 toxicity.
ClinicalTrials.gov ID: NCT04248569
TrialFetch AI summary: Pediatric and young adult patients (1–21 years) with relapsed/refractory, AFP-high (≥100 ng/mL), HLA-A2–positive hepatoblastoma, HCN-NOS, or HCC receive a single infusion of autologous ET140203 T cells after lymphodepletion. ET140203 (JWATM-203) is an engineered T-cell therapy using an ARTEMIS receptor with a TCR-mimic that targets AFP158–166/HLA-A*02:01 to selectively kill AFP+/HLA-A2+ liver cancer cells.
ClinicalTrials.gov ID: NCT04634357
TrialFetch AI summary: Adults with advanced primary liver cancers (HCC or cholangiocarcinoma) or solid tumors with liver‑predominant metastases (≤2 extrahepatic sites), ECOG 0–1, receive oral AU409 in 28‑day cycles. AU409 is a first‑in‑class small‑molecule RNA transcription modulator designed to alter liver cancer transcription programs; key exclusions include untreated/symptomatic CNS metastases, significant cardiac risk, Child‑Pugh ≥B7 (for HCC), and strong CYP inducer/inhibitor use.
ClinicalTrials.gov ID: NCT05791448